€214.00
2.15% today
Xetra, Jun 19, 05:30 pm CET
ISIN
DE0007165631
Symbol
SRT3
Index
Sector

Sartorius Vz Stock price

€215.20
-14.80 6.43% 1M
-0.80 0.37% 6M
+0.00 0.00% YTD
+5.80 2.77% 1Y
-77.40 26.45% 5Y
+175.36 440.19% 10Y
+210.73 4,708.94% 20Y
Xetra, Closing price Thu, Jun 19 2025
+5.70 2.72%
ISIN
DE0007165631
Symbol
SRT3
Index
Sector

Key metrics

Market capitalization €13.12b
Enterprise Value €16.87b
P/E (TTM) P/E ratio 150.72
EV/FCF (TTM) EV/FCF 23.69
EV/Sales (TTM) EV/Sales 4.90
P/S ratio (TTM) P/S ratio 3.81
P/B ratio (TTM) P/B ratio 5.34
Dividend yield 0.35%
Last dividend (FY24) €0.74
Revenue growth (TTM) Revenue growth 3.99%
Revenue (TTM) Revenue €3.44b
EBIT (operating result TTM) EBIT €407.20m
Free Cash Flow (TTM) Free Cash Flow €712.30m
Cash position €877.10m
EPS (TTM) EPS €1.39
P/E forward 61.47
P/S forward 3.66
EV/Sales forward 4.71
Show more

Create a Free Account to create an Sartorius Vz alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Sartorius Vz Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Sartorius Vz forecast:

14x Buy
58%
9x Hold
38%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Sartorius Vz forecast:

Buy
58%
Hold
38%
Sell
4%

Financial data from Sartorius Vz

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,444 3,444
4% 4%
100%
- Direct Costs 1,885 1,885
4% 4%
55%
1,559 1,559
4% 4%
45%
- Selling and Administrative Expenses 892 892
4% 4%
26%
- Research and Development Expense 202 202
19% 19%
6%
831 831
2% 2%
24%
- Depreciation and Amortization 424 424
16% 16%
12%
EBIT (Operating Income) EBIT 407 407
9% 9%
12%
Net Profit 96 96
36% 36%
3%

In millions EUR.

Don't miss a Thing! We will send you all news about Sartorius Vz directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sartorius Vz Stock News

AD HOC NEWS
2 days ago
Die britische Investmentbank Barclays hat das Kursziel für Sartorius DE0007165631 von 320 auf 310 Euro gesenkt, aber die Einstufung auf "Overweight" belassen.
AD HOC NEWS
14 days ago
Die Schweizer Großbank UBS hat das Kursziel für Sartorius DE0007165631 von 302 auf 230 Euro gesenkt, aber die Einstufung auf "Neutral" belassen.
AD HOC NEWS
30 days ago
Die kanadische Bank RBC hat das Kursziel für die Aktien des Laborzulieferers Sartorius DE0007165631 von 275 auf 260 Euro gesenkt und die Einstufung auf "Sector Perform" belassen.
More Sartorius Vz News

Company Profile

Sartorius AG is an international laboratory and process technology provider for the biotech, pharmaceutical, and food industries. It operates through the Bioprocess Solutions and Lab Products and Services divisions. The Bioprocess Solutions division focuses on the major areas of activity of filtration, fluid management, fermentation, and purification. The Lab Products and Services division focuses on lab balances, pipettes, and laboratory water purification systems. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.

Head office Germany
CEO Joachim Kreuzburg
Employees 13,573
Founded 1870
Website www.sartorius.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today